AUSTIN, Texas, May 4, 2015 /PRNewswire/ -- Luminex Corporation
(NASDAQ:LMNX) today announced financial results for the first
quarter ended March 31, 2015.
Financial and operating highlights include the following:
- Consolidated first quarter revenue of $57.7 million, a 2 percent increase over the
first quarter of 2014.
- First quarter assay revenue of $25.4
million, a 17 percent increase over the first quarter of
2014.
- Consolidated gross profit margin was 70 percent for the first
quarter of 2015.
- GAAP net income for the first quarter was $7.5 million or $0.18 per diluted share. Non-GAAP net income for
the first quarter was $9.6 million,
or $0.23 per diluted share (see
Non-GAAP reconciliation).
- Initiated clinical trials for the ARIES™ System, ARIES™ HSV
1&2 Assay and NxTAG™ Respiratory Pathogen Panel.
"I am very pleased with the operational and financial
performance for the first quarter of 2015. In spite of the
consumable challenges at our largest partner, we achieved overall
revenue growth of more than 2% compared with the first quarter of
2014. During the quarter we made significant progress on our
transformational pipeline products, including initiating clinical
trials for both ARIES and NxTAG. We also achieved the highest level
of assay revenues in the Company's history and delivered solid
margins and operating cash flow," said Homi
Shamir, President and Chief Executive Officer of
Luminex.
REVENUE
SUMMARY
(in thousands,
except percentages)
|
|
|
|
|
|
|
|
Three Months
Ended
|
|
|
|
|
|
March
31,
|
|
Variance
|
|
2015
|
|
2014
|
|
($)
|
|
(%)
|
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
System
sales
|
$ 5,964
|
|
$ 6,400
|
|
$ (436)
|
|
-7%
|
Consumable
sales
|
9,896
|
|
12,768
|
|
(2,872)
|
|
-22%
|
Royalty
revenue
|
10,702
|
|
10,049
|
|
653
|
|
6%
|
Assay
revenue
|
25,446
|
|
21,660
|
|
3,786
|
|
17%
|
All other
revenue
|
5,733
|
|
5,684
|
|
49
|
|
1%
|
|
$ 57,741
|
|
$ 56,561
|
|
$ 1,180
|
|
2%
|
Additional Financial Highlights:
- Infectious disease assay sales were approximately 64 percent of
total assay sales for the quarter and genetic testing assays were
36 percent.
- Royalty revenues reflect total royalty-bearing end user sales
for the quarter of $126.9
million.
- During the quarter, there were 16 bulk purchases of consumables
totaling $7.2 million, or 73 percent
of total consumable sales.
- 193 multiplexing analyzers were shipped during the quarter,
which included 86 MAGPIX systems, 91 LX systems, and 16 FLEXMAP 3D
systems.
- GAAP operating income for the first quarter was $9.7 million. Non-GAAP operating income was
$12.6 million (see Non-GAAP
reconciliation).
- Cash and investments balance at quarter-end totaled
$110.9 million.
- Days sales outstanding (DSO) was 39 days at quarter-end.
FINANCIAL OUTLOOK AND GUIDANCE
The Company reaffirms its 2015 annual revenue guidance of
between $230 million and $236
million. In addition, the Company anticipates second quarter
2015 revenue to be between $56 million and
$58 million.
CONFERENCE CALL
Management will host a conference call at 3:30 p.m. CDT/4:30 p.m.
EDT, Monday, May 4, 2015 to
discuss the operating highlights and financial results for the
first quarter ended March 31, 2015.
The conference call will be webcast live and may be accessed at
Luminex Corporation's website at http://www.luminexcorp.com.
Simply log on to the web at the address above, go to the
Company section and access the Investor Relations link. Please go
to the website at least 15 minutes prior to the call to
register, download and install any necessary audio/video software.
If you are unable to participate during the live webcast, the call
will be archived for six months on the website using the 'replay'
link.
Luminex develops, manufactures and markets proprietary
biological testing technologies with applications throughout the
life sciences industry. The Company's xMAP system is an
open-architecture, multi-analyte technology platform that delivers
fast, accurate and cost-effective bioassay results to markets as
diverse as pharmaceutical drug discovery, clinical diagnostics and
biomedical research, including the genomics and proteomics research
markets. The Company's xMAP technology is sold worldwide and is in
use in leading research laboratories as well as major
pharmaceutical, diagnostic and biotechnology companies.
Further information on Luminex or xMAP can be obtained on the
Internet at http://www.luminexcorp.com.
Statements made in this release that express Luminex's or
management's intentions, plans, beliefs, expectations or
predictions of future events are forward-looking statements.
Forward-looking statements in this release include statements
regarding: the expansion of our installed base of multiplexing
systems; customer inventories of our consumable products; the
development progress of our pipeline products, including ARIES and
NxTAG products, market acceptance of our products, including
instruments, consumables and assays, regulatory clearance of our
products; the ability of our investment in current initiatives and
new products to drive long-term value for our shareholders; and,
projected 2015 performance, including revenue guidance. The words
"believe," "expect," "intend," "estimate," "anticipate," "will,"
"could," "should" and similar expressions are intended to further
identify such forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995. It is
important to note that the Company's actual results or performance
could differ materially from those anticipated or projected in such
forward-looking statements. Factors that could cause
Luminex's actual results or performance to differ materially
include risks and uncertainties relating to, among others, market
demand and acceptance of Luminex's products and technology, the
Company's dependence on strategic partners for development,
commercialization and distribution of products, concentration of
the Company's revenue in a limited number of strategic partners,
fluctuations in quarterly results due to a lengthy and
unpredictable sales cycle and bulk purchases of consumables, our
ability to sell products directly to end users, our ability to
launch products on time that satisfy market needs with products
that we sell, setting of medicare reimbursement codes that
adequately reflect the value of our products, Luminex's ability to
scale manufacturing operations and manage operating expenses, gross
margins and inventory levels, potential shortages of components,
competition, the timing of regulatory approvals, the
implementation, including any modification, of the Company's
strategic operating plans, the uncertainty regarding the outcome or
expense of any litigation brought against Luminex, risks relating
to Luminex's foreign operations, risks and uncertainties associated
with implementing our acquisition strategy and the ability to
integrate acquired companies (or selected assets) into our
consolidated business operations, including the ability to
recognize the benefits of our acquisitions, as well as the risks
discussed under the heading "Risk Factors" in Luminex's Reports on
Forms 10-K and 10-Q, as filed with the Securities and Exchange
Commission. The forward-looking statements, including the
financial guidance and 2015 outlook, contained herein represent the
judgment of Luminex as of the date of this press release, and
Luminex expressly disclaims any intent, obligation or undertaking
to release publicly any updates or revisions to any forward-looking
statements to reflect any change in Luminex's expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based.
Contacts:
|
Harriss T.
Currie
|
Matt
Norman
|
|
Sr. Vice President,
Finance
|
Manager, Government
and Investor
|
|
and Chief Financial
Officer
|
Relations
|
|
512-219-8020
|
512-219-8020
|
|
hcurrie@luminexcorp.com
|
mnorman@luminexcorp.com
|
LUMINEX
CORPORATION
|
CONDENSED
CONSOLIDATED BALANCE SHEETS
|
(in
thousands)
|
|
|
|
|
|
March
31,
|
|
December
31,
|
|
2015
|
|
2014
|
|
(unaudited)
|
|
|
ASSETS
|
|
|
|
Current
assets:
|
|
|
|
Cash and cash
equivalents
|
$ 94,907
|
|
$
91,694
|
Accounts receivable,
net
|
25,139
|
|
29,095
|
Inventories,
net
|
33,723
|
|
36,616
|
Deferred income
taxes
|
11,336
|
|
12,203
|
Prepaids and
other
|
7,114
|
|
7,412
|
Total current
assets
|
172,219
|
|
177,020
|
Property and
equipment, net
|
46,717
|
|
39,945
|
Intangible assets,
net
|
55,480
|
|
56,382
|
Deferred income
taxes
|
15,045
|
|
15,400
|
Long-term
investments
|
16,008
|
|
15,975
|
Goodwill
|
49,619
|
|
49,619
|
Other
|
2,980
|
|
3,185
|
Total
assets
|
$ 358,068
|
|
$ 357,526
|
LIABILITIES AND
STOCKHOLDERS' EQUITY
|
|
|
|
Current
liabilities:
|
|
|
|
Accounts
payable
|
$ 10,973
|
|
$
11,841
|
Accrued
liabilities
|
8,403
|
|
14,118
|
Deferred
revenue
|
4,692
|
|
4,407
|
Total current
liabilities
|
24,068
|
|
30,366
|
Deferred
revenue
|
2,221
|
|
2,297
|
Other
|
4,708
|
|
4,869
|
Total
liabilities
|
30,997
|
|
37,532
|
Stockholders'
equity:
|
|
|
|
Common
stock
|
42
|
|
42
|
Additional paid-in
capital
|
309,501
|
|
309,424
|
Accumulated other
comprehensive (loss) income
|
(1,197)
|
|
(744)
|
Retained
earnings
|
18,725
|
|
11,272
|
Total stockholders'
equity
|
327,071
|
|
319,994
|
Total liabilities and
stockholders' equity
|
$ 358,068
|
|
$ 357,526
|
LUMINEX
CORPORATION
|
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
|
(in thousands,
except per share amounts)
|
|
|
|
|
|
Three Months
Ended
|
|
March
31,
|
|
2015
|
|
2014
|
|
(unaudited)
|
|
|
|
|
Revenue
|
$57,741
|
|
$56,561
|
Cost of
revenue
|
17,522
|
|
16,607
|
Gross
profit
|
40,219
|
|
39,954
|
Operating
expenses:
|
|
|
|
Research and
development
|
10,145
|
|
11,084
|
Selling, general and
administrative
|
19,479
|
|
19,445
|
Amortization of
acquired intangible assets
|
902
|
|
1,020
|
Restructuring
costs
|
-
|
|
220
|
Total operating
expenses
|
30,526
|
|
31,769
|
Income from
operations
|
9,693
|
|
8,185
|
Interest expense from
long-term debt
|
-
|
|
(6)
|
Other income,
net
|
694
|
|
(19)
|
Income before income
taxes
|
10,387
|
|
8,160
|
Income tax
expense
|
(2,934)
|
|
(2,194)
|
Net income
|
$ 7,453
|
|
$ 5,966
|
Net income per share,
basic
|
$ 0.18
|
|
$ 0.14
|
Shares used in
computing net income per share, basic
|
41,873
|
|
41,209
|
Net income per share,
diluted
|
$ 0.18
|
|
$ 0.14
|
Shares used in
computing net income per share, diluted
|
42,194
|
|
41,825
|
LUMINEX
CORPORATION
|
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
(in
thousands)
|
|
|
|
|
|
Three Months
Ended
|
|
March
31,
|
|
2015
|
|
2014
|
|
(unaudited)
|
Cash flows from
operating activities:
|
|
|
|
Net income
|
$ 7,453
|
|
$ 5,966
|
Adjustments to
reconcile net income to net cash provided by operating
activities:
|
|
|
|
Depreciation and
amortization
|
3,198
|
|
3,928
|
Stock-based
compensation
|
1,579
|
|
1,629
|
Deferred income tax
(benefit) expense
|
877
|
|
678
|
(Gain) loss on sale
or disposal of assets
|
(893)
|
|
5
|
Non-cash
restructuring charges
|
-
|
|
772
|
Other
|
(153)
|
|
(192)
|
Changes in operating
assets and liabilities:
|
|
|
|
Accounts receivable,
net
|
3,946
|
|
4,017
|
Inventories,
net
|
2,928
|
|
(899)
|
Other
assets
|
324
|
|
332
|
Accounts
payable
|
(842)
|
|
(2,581)
|
Accrued
liabilities
|
(7,689)
|
|
(2,434)
|
Deferred
revenue
|
207
|
|
216
|
Net cash provided by
operating activities
|
10,935
|
|
11,437
|
Cash flows from
investing activities:
|
|
|
|
Purchases of
available-for-sale securities
|
-
|
|
(2,996)
|
Sales and maturities
of available-for-sale securities
|
-
|
|
2,997
|
Purchase of property
and equipment
|
(8,898)
|
|
(3,105)
|
Proceeds from sale of
assets
|
893
|
|
-
|
Acquired technology
rights
|
(177)
|
|
-
|
Net cash used in
investing activities
|
(8,182)
|
|
(3,104)
|
Cash flows from
financing activities:
|
|
|
|
Proceeds from
employee stock plans and issuance of common stock
|
405
|
|
1,102
|
Net cash provided by
financing activities
|
405
|
|
1,102
|
Effect of foreign
currency exchange rate on cash
|
55
|
|
27
|
Change in cash and
cash equivalents
|
3,213
|
|
9,462
|
Cash and cash
equivalents, beginning of period
|
91,694
|
|
67,924
|
Cash and cash
equivalents, end of period
|
$94,907
|
|
$77,386
|
LUMINEX
CORPORATION
|
NON-GAAP
RECONCILIATION
|
(in
thousands)
|
|
|
|
|
|
Three Months
Ended
|
|
March
31,
|
|
2015
|
|
2014
|
|
(unaudited)
|
|
|
|
|
Income from
operations
|
$ 9,693
|
|
$ 8,185
|
Stock-based
compensation
|
1,579
|
|
1,629
|
Amortization of
acquired intangible assets
|
902
|
|
1,020
|
Costs associated with
legal proceedings
|
437
|
|
790
|
Severance
costs
|
37
|
|
45
|
Restructuring
costs
|
-
|
|
810
|
Adjusted income from
operations
|
$12,648
|
|
$12,479
|
Interest expense from
long-term debt
|
-
|
|
(6)
|
Other income,
net
|
694
|
|
(19)
|
Gain on sale of cost
method equity investment
|
(892)
|
|
-
|
Settlement of
litigation
|
200
|
|
-
|
Income tax
expense
|
(2,934)
|
|
(2,194)
|
Income tax effect of
above adjusting items
|
(130)
|
|
(388)
|
Adjusted net
income
|
$ 9,586
|
|
$ 9,872
|
Adjusted net income
per share, basic
|
$ 0.23
|
|
$ 0.24
|
Shares used in
computing adjusted net income per share, basic
|
41,873
|
|
41,209
|
Adjusted net income
per share, diluted
|
$ 0.23
|
|
$ 0.24
|
Shares used in
computing adjusted net income per share, diluted
|
42,194
|
|
41,825
|
The Company makes reference in this release to "non-GAAP
operating income" and "non-GAAP net income" which excludes
stock-based compensation expense, amortization of acquired
intangible assets and the impact of costs associated with legal
proceedings, which are unpredictable and can vary significantly
from period to period, including costs associated with the ENZO
Life Sciences, Inc. and Irori Technologies, Inc. complaints
discussed in the Legal Proceedings section of our previously filed
10-K and 10-Qs and certain other recurring and non-recurring
expenses. The Company believes that excluding these items and their
related tax effects from its financial results reflects operating
results that are more indicative of the Company's ongoing operating
performance while improving comparability to prior periods, and, as
such may provide investors with an enhanced understanding of the
Company's past financial performance and prospects for the future.
In addition, the Company's management uses such non-GAAP measures
internally to evaluate and assess its core operations and to make
ongoing operating decisions. This information is not intended to be
considered in isolation or as a substitute for income from
operations, net income, net income per share or expense information
prepared in accordance with GAAP
Logo -
http://photos.prnewswire.com/prnh/20150201/172702LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/luminex-corporation-reports-first-quarter-2015-results-300076801.html
SOURCE Luminex Corporation